Study S000105

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05220917
Acronym: CER-4-T2D
Study type: OBSERVATIONAL
Status: ACTIVE_NOT_RECRUITING
Enrollment: 781430
Start: 2021-08-01
Primary completion: 2026-05-31
Lead sponsor: Brigham and Women's Hospital
Conditions: Cardiovascular Events; Type2 Diabetes; Renal Disease
Interventions: DRUG:SGLT2 inhibitor; DRUG:DPP-4 inhibitor; DRUG:GLP-1RA; DRUG:2nd generation SU
Results posted: FALSE

Registered primary outcomes

MACE [through study completion, an average of 1 year]
Modified MACE [through study completion, an average of 1 year]
Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF) [through study completion, an average of 1 year]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.